Liver necrosis and fulminant hepatic failure in rats: protection by oxyanionic form of tungsten  by Pawa, Sonica & Ali, Shakir
www.bba-direct.com
Biochimica et Biophysica Acta 1688 (2004) 210–222Liver necrosis and fulminant hepatic failure in rats:
protection by oxyanionic form of tungsten
Sonica Pawa, Shakir Ali*
Department of Biochemistry, Faculty of Science, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi-11 00 62, IndiaReceived 21 January 2003; received in revised form 24 September 2003; accepted 5 December 2003Abstract
The hepatic lesion produced as a result of oxidative stress is of wide occurrence. In the present study, the effect of tungsten on liver
necrosis and fulminant hepatic failure (FHF) has been studied in rats treated with various compounds known to produce oxidative stress.
Supplementation of animals with sodium tungstate for 7 weeks before the induction of liver injury by chemicals including thioacetamide
(TAA), carbon tetrachloride (CCl4), or chloroform (CHCl3) could protect progression of hepatic injury. Various biochemical changes
associated with liver damage and oxidative stress were measured. Hepatic malondialdehyde content, endogenous tripeptide, and reduced
glutathione were measured as oxidative stress markers. The activity of xanthine oxidase, which generates reactive oxygen species (ROS) as a
by-product, was also determined and found to be perturbed. Tungsten supplementation to rats caused a significant decrease in lipid
peroxidation and lowered the levels of the biochemical markers of hepatic lesions produced by TAA, CCl4 (CCl4), or CHCl3. Tungsten could
also cause an increase in the survival rate in rats receiving lethal doses of TAA, CCl4, or CHCl3. The protective effect of tungsten, however, is
suggested to be limited to the conditions where the hepatic lesion is reported to be due to the generation of ROS. The progression of liver
injury produced by the compounds causing oxidative stress without initiating the generation of free radicals such as bromobenzene (BB), or
acetaminophen (AAP), could not be inhibited by tungsten. The possible mechanism explaining the role of oxyanionic form of tungsten in free
radical-induced hepatic lesions is discussed.
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1. Introduction FHF by chemicals such as carbon tetrachloride (CCl ) [3],Hepatic injuries such as necrosis and fulminant hepatic
failure (FHF), which are often produced on exposure of the
tissue to virus or many chemical agents [1], constitute a
major health hazard. Liver necrosis and FHF are the two
important clinical conditions of liver. Necrosis is a com-
plex process, characterized by the simultaneous activation
of multiple deregulated pathways that culminate in the loss
of cell membrane integrity causing leakage of cellular
constituents. FHF, on the other hand, is a rare but very
lethal hepatic disorder characterized by an acute onset of
severe hepatic dysfunction in the absence of preexisting
liver disease that results in jaundice, hepatic encephalop-
athy and coagulopathy [2]. The underlying mechanisms
leading to the generation of hepatic lesions in necrosis and0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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thioacetamide (TAA) [4], chloroform (CHCl3) [5], bromo-
benzene (BB) [6], and acetaminophen (AAP) [7] are fairly
well documented. While TAA, CCl4 and CHCl3 inflict
tissue injury by producing reactive oxygen species (ROS),
thereby directly promoting the peroxidation of membrane
lipids [8–10], compounds like BB and AAP are first
metabolized to electrophilic intermediates, which readily
conjugate with reduced glutathione (GSH) leading to its
depletion. In both the conditions, oxidative stress ensues
[11,12].
The oxyanionic forms of the elements are their stable
forms in high oxidation states. In this form, an element can
cross cell membranes using the normal phosphate and/or
sulfate transport systems of the cell [13]. Once inside the
cell, oxyanions may catalyze different reactions like the
sulfuryl transfer reactions and have many effects [14,15].
Tungstate is a relatively less biologically studied form of
an oxyanion. Its detection in rat liver and kidney points
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although no conclusive evidences are available. In labora-
tory animals, the retention of tungstate in liver, spleen and
bones is < 1 mg/100 g [17], 3 mg/100 g [18], and 18 mg/
100 g [19], respectively. Dietary intake of tungstate by
humans and animals is low [20]. In the present study, we
demonstrate the interaction of tungstate with the liver
tissue under stress conditions. The study reports that
tungstate can protect the hepatic lesions produced by the
administration of compounds like TAA, CCl4, or CHCl3.
Tungstate could not only prevent liver necrosis, but was
also effective in FHF. The mechanism explaining the role
of tungstate in inhibiting the progression of hepatic injury
is discussed. The chemicals used in this study have been
widely used to inflict liver injury in experimental animals.
Humans are likely to experience the toxicity being inves-
tigated in rat model. While CHCl3 and AAP are consumed
as medicine, BB and CCl4 are industrial compounds and
pose threat of occupational exposure to humans. TAA was
previously used to prevent orange decay [21]. The tissue
injury caused by its chronic administration mimics the
pattern of liver injury seen in humans [22].2. Materials and methods
2.1. Animals and other materials
Adult female albino Wistar rats (weighing 150–200 g)
were obtained from and kept in the Central Animal House
Facility of Jamia Hamdard in propylene cages in an envi-
ronmentally controlled room with a 12-h light–dark cycle at
room temperature (25F 2 jC), with each group containing
six rats. Animals had free access to standard pellet diet and
tap water ad libitum. Guidelines issued by the Animal Ethics
Committee for the care and use of laboratory animals was
followed. All the chemicals used in this study except TAA
were of highest purity grade available from standard com-
mercial sources in India. TAA was procured from Sigma
Chem. Co.
2.2. Induction of liver necrosis
Acute liver injury was induced in different groups of rats
by administering a single intraperitoneal injection of CCl4
(1.5 ml/kg b.wt. of 80% CCl4 in corn oil), or BB (0.5 ml/kg
b.wt. of 80% BB in corn oil), or CHCl3 (1.0 ml/kg b.wt. of
80% CHCl3 in corn oil). For TAA model, a single injection
(400 mg/kg b.wt. of TAA, dissolved in normal saline) was
given intraperitoneally. Dose of AAP was also prepared in
normal saline, and administered p.o. as a single dose (2 g/kg
b.wt.). All these doses had previously been standardized in
our laboratory, and are established to reproduce a model of
hepatic injury in Wistar rats. Rats receiving a similar volume
of normal saline, corn oil, or sodium tungstate served as
controls.2.3. Induction of FHF
For induction of FHF, rats were given three intraperito-
neal injections of TAA (400 mg/kg b.wt.) at 24-h interval, as
per the protocol described by Bruck et al. [23]. Supportive
therapy by subcutaneous administration of 5% dextrose (25
ml/kg b.wt.) and 0.9% NaCl with potassium (20 mEq/l) was
given every 12 h to avoid weight loss, hypoglycemia, and
renal failure, as described by Geller [24]. Control rats
received a similar volume of normal saline or sodium
tungstate.
2.4. Processing of the tissue and biochemical estimations
Each animal was weighed before killing. Total liver
weight of individual rats from each group was also
recorded before the tissue was processed for analyses.
Liver injury was evaluated by analyzing serum/tissue
lysate obtained from rats sacrificed 24 h after receiving
the necrogenic dose of the respective hepatotoxins. In FHF,
rats were sacrificed 4 h after TAA administration. Rats
were anesthetized with ether and the blood was drawn by
cardiac puncture. Blood was allowed to clot and the serum
was separated by centrifugation at 1000 g for 10 min.
Serum was used for the analysis of aminotransferases and
alkaline phosphatase (ALP) levels using diagnostic kits.
The liver of the rat was immediately removed, washed in
ice-cold saline solution and blotted. Accurately weighed
pieces of tissue were minced and homogenized in nine
volumes of 0.1 M phosphate buffer (pH 7.4), containing
1.15% KCl, using a polytron homogenizer. A portion of
the homogenate was kept for the determination of malon-
dialdehyde and reduced glutathione content. The rest of the
homogenate was subjected to differential centrifugation in
a cooling centrifuge initially at 800 g for 10 min (to
remove the nuclei and other cell debris), and then at
9500 g for 20 min to get the postmitochondrial super-
natant (PMS).
Aminotransferase (alanine aminotransferase and aspar-
tate aminotransferase) activities were estimated using di-
agnostic kits based on the methods described by Reitman
and Frankel [25]. For alanine aminotransferase (ALT), 0.1
ml of enzyme source was diluted to 1.0 ml with a-
ketoglutarate-alanine buffer substrate at pH 7.4, and for
aspartate aminotransferase (AST), with a-ketoglutarate-
aspartate buffer substrate at pH 7.4. Reaction mixture
was then incubated at 37 jC for 30 min in case of ALT
and for 60 min in case of AST. Half of a ml of
dinitrophenylhydrazine (19.8 mg in 100 ml of HCl) was
then added followed by the addition of 5 ml of 0.4 N
NaOH. The activity was determined by measuring the
absorbance at 505 nm. Results are expressed as U/ml,
where one unit is defined as one Amole of pyruvate formed
under defined conditions per ml of serum. ALP was
measured according to the method of Bessey et al. [26].
In brief, reaction mixture consisting of 0.1 ml of serum
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(pH 10.4) at room temperature for 30 min. The alkaline-
buffered substrate was prepared by taking equal volume of
0.1 M glycine buffer and 0.4% p-nitrophenyl phosphate
(PNPP). The absorbance was recorded at 410 nm before
and after the addition of 50 Al of 1 M HCl. Enzyme
activity was expressed in equivalent units/ml, where one
unit is defined as 1 Amol of p-nitrophenol (PNP) formed
under defined conditions per milliliter of serum.
Malondialdehyde content was measured as thiobarbituric
acid reacting substances (TBARS) in the liver homogenate
[27]. Reaction mixture consisting of the enzyme source (0.2
ml) and the phosphate buffer (0.1 M, pH 7.4) was kept at 37
jC in a shaker water bath for 1 h. The reaction was
terminated by precipitating the enzyme with 10% trichloro-
acetic acid followed by the addition of 0.67% thiobarbituric
acid. All the tubes were kept in boiling water bath for 20
min, then cooled in ice and centrifuged at 2500 g for 10
min. Presence of malondialdehyde was determined spectro-
photometrically in the pink supernatant at 432 nm. Results
are expressed as nanomoles of malondialdehyde per milli-
gram of protein.
The content of reduced glutathione was assayed accord-
ing to the method of Jollow et al. [28] by the spectropho-
tometric determination of a yellow-colored complex, 5-thio-
2-nitrobenzoate at 412 nm. One milliliter of the homogenate
was precipitated with 1.0 ml of 4% sulfosalicylic acid. The
samples were kept for an hour at 4 jC and then centrifuged
at 1200 g for 15 min in a cooling centrifuge. The reaction
mixture consisted of 0.1 ml of supernatant, 2.7 ml of 0.1 M
of phosphate buffer at pH 7.4 and 0.2 ml of 5,5V-dithiobis-2-
nitrobenzene (40 mg in 10 ml of phosphate buffer) in a total
volume of 3.0 ml. Results are expressed as micromoles of
GSH per gram of liver.
Xanthine oxidase was assayed according to the method
described by Stirpe and Della Corte [29]. Reaction mixture
consisting of 1.0 mM xanthine and 0.5 M Tris–HCl buffer
(pH 8.1) was incubated with 0.2 ml of PMS for 20 min at 37
jC. After precipitating the enzyme with 10% perchloric
acid, the mixture was centrifuged at 1200 g for 10 min.
Absorbance of uric acid in the clear supernatant was
recorded at 290 nm using a spectrophotometer. Results are
expressed as micromoles of uric acid formed per milligram
of protein. The protein content of each biological sample
was determined according to Lowry’s method [30] using
bovine serum albumin as reference standard.
2.5. Experimental design
To evaluate the anti-hepatotoxic effect of tungsten
against hepatic necrosis induced by different hepatotoxins,
sodium tungstate (50 mg/kg b.wt.) was administered to rats
orally for 7 weeks followed by the necrogenic dose of each
of the hepatotoxin to various groups. In the group intended
for the study of FHF, sodium tungstate (50 mg/kg b.wt.)
was administered similarly to rats orally for 7 weeksfollowed by TAA. Groups of rats treated with normal
saline, or corn oil, or with tungstate alone served as normal
controls. The groups administered with the hepatotoxin
alone served as positive controls. All the biochemical
parameters mentioned in the above section of this text
were estimated in the experimental as well as the control
group of rats sacrificed 24 h after the hepatotoxin admin-
istration in necrosis, and after 4 h in FHF. It was ensured
that all the animals, treated or untreated, are sacrificed at
the same time point. All the biochemical estimations were
completed at 0–4 jC on the same day when the animals
were sacrificed.
2.6. Survival studies
These experiments were performed to examine the
protective effect of tungsten on survival in rats receiving
lethal dose (LD90) of various hepatotoxins. Animals for
these studies were divided into different groups, each
containing 10 rats. Mortality was induced by administering
lethal doses of CCl4 (50% CCl4 in corn oil at a dose of 4
ml/kg b.wt. orally for 19 days), BB (50% BB in corn oil at
a dose of 1 ml/kg b.wt. orally for 14 days), or CHCl3 (50%
CHCl3 in corn oil at a dose of 1.5 ml/kg b.wt. orally for 13
days). AAP and TAA, respectively, were given at a dose of
2 g/kg b.wt. orally for 17 days, and at a dose of 150 mg/kg
b.wt. orally for 12 days. To assess the protective effect of
tungsten on survival, animals in each group were gavaged
sodium tungstate (50 mg/kg b.wt.) for 7 weeks followed by
the administration of lethal dose (LD90) of the respective
hepatotoxin. The group of rats given normal saline or corn
oil or tungstate alone for similar duration, and by the same
route, served as controls. The mortality in each group was
recorded daily for 2 weeks after the last dose of the
respective toxin was administered. Results are expressed
after calculating the percent of animals surviving in each
group.
2.7. Histopathological studies
For histopathological studies, few-millimeter-thick mid-
sections of the left lobes of the livers excised from each
group were processed for light microscopy. The process-
ing involved fixing of the tissue specimens in a 10%
neutral buffered formalin solution, preparing the blocks in
paraffin, cutting sections 5–6 Am in thickness, and stain-
ing the sections with haematoxylin–eosin stain. The
sections were scanned and analyzed by an expert pathol-
ogist who was not aware of sample assignment to exper-
imental groups.
2.8. Effect of allopurinol or dimethyl sulfoxide (DMSO) on
hepatic injury
Allopurinol (AP), a xanthine oxidase inhibitor, or
DMSO, a ROS scavenger, was given orally for 3 consecu-
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atotoxins. AP was administered at a dose level of 30 mg/kg
b.wt., while the dose of ROS scavenger was 4.0 g/kg b.wt.
Animals were sacrificed 24 h after hepatotoxin administra-
tion; their tissue/serum samples were collected and assayed
for liver function tests and lipid peroxidation as a marker of
oxidative stress.
2.9. Statistical analysis
Data are expressed as meansF S.E.M. and analyzed by
one-way analysis of variance. In each case, hepatotoxin
alone treated group was compared with the group supple-
mented with tungsten followed by necrogenic dose of the
respective hepatotoxin. Levels of statistical significance
were **P < 0.01, *P < 0.05, and §P < 0.1.Fig. 2. Serum aspartate transaminase level in various groups of rats treated
with sodium tungstate followed by induction of necrosis by different
hepatotoxins. Dose and the treatment protocol have been described in the
text. Rats were sacrificed 24 h after the administration of each hepatotoxin.
Data are expressed as meansF S.E.M. (n= 6) and analyzed by one-way
analysis of variance. Normal control: 136.6F 6.07 and sodium tungstate:
138.2F 5.24. In each case, the hepatotoxin alone treated group was
compared with the group supplemented with sodium tungstate followed by
necrogenic dose of the respective hepatotoxin. The levels of statistical
significance were **P< 0.01 and §P < 0.1.3. Results
The prophylactic role of tungstate in various models of
hepatic injury was studied by monitoring the activity levels
of serum marker enzymes and oxidative stress markers. To
discern the source of ROS involved in the pathogenesis, the
activity of the pro-oxidant enzyme, xanthine oxidase, was
determined. This enzyme has been reported to contribute to
tissue injury by generating ROS. The findings of the study
are outlined below.Fig. 1. Activity of serum alanine transaminase in rats treated with sodium
tungstate followed by the necrogenic dose of respective hepatotoxins to
various groups of rats as per the treatment protocol described in the text. Rats
were sacrificed 24 h after the administration of each hepatotoxin. Data are
expressed as meansF S.E.M. (n= 6) and analyzed by one-way analysis of
variance. Normal control: 32.3F 3.77 and sodium tungstate: 31.8F 3.36. In
each case, the hepatotoxin alone treated group was compared with the group
supplemented with sodium tungstate followed by necrogenic dose of the
respective hepatotoxin. The levels of statistical significance were **P< 0.01
and *P< 0.05.3.1. Effect of tungstate on serum enzymes in liver necrosis
The activity levels of serum aminotransferases (sALT
and sAST) and alkaline phosphatase (sALP) were found to
be elevated significantly in rats sacrificed 24 h after re-
ceiving the necrogenic dose of each of the hepatotoxins
used in this study. These enzymes are generally elevated in
different types of hepatic lesions [31,32]. As shown in Fig.
1, sALT activity, which increased remarkably in CCl4 alone
treated group, appears to be normalized in group pretreated
with tungstate followed by CCl4 exposure (241.2F 7.33 vs.
186.2F 5.72). A similar effect was observed in tungstate-
pretreated TAA group (106.2F 5.66 vs. 58.4F 5.00) and
tungstate-pretreated CHCl3 group. However, no decrease in
the sALT activity by tungsate was seen in rats with BB- or
AAP-induced acute liver injury, which may be attributed to
the specific type of damage reported with these com-
pounds. Almost similar results were obtained with sAST
(Fig. 2).
The effect of tungstate pretreatment on sALP activity in
hepatic necrosis induced by different hepatotoxins is
shown in Fig. 3. Consistent with the results of trans-
aminases, a significant decrease in sALP activity was
found in groups pretreated with tungstate followed by
CCl4, TAA, or CHCl3. However, no statistically significant
difference was observed when groups treated with BB or
AAP alone were compared with the tungstate-pretreated
BB (9.90F 0.49 vs. 10.16F 0.59), or AAP (14.10F 0.46
vs. 13.90F 0.51) groups.
Fig. 3. Effect of sodium tungstate pretreatment on sALP activity in necrosis
induced in various groups of rats by different hepatotoxins as per the
treatment protocol described in the text. Rats were sacrificed 24 h after the
administration of each hepatotoxin. Data are expressed as meansF S.E.M.
(n= 6) and analyzed by one-way analysis of variance. Normal control:
7.08F 0.10 and sodium tungstate: 6.70F 0.13. In each case, the
hepatotoxin alone treated group was compared with the group supple-
mented with sodium tungstate followed by necrogenic dose of the
respective hepatotoxin. The level of statistical significance was **P < 0.01.
Fig. 4. Hepatic lipid peroxidation, measured as malondialdehyde levels per
milligram of protein, in rats treated with sodium tungstate followed by
necrogenic dose of different hepatotoxins administered to various groups of
rats. Dose and the treatment protocol have been described in the text. Rats
were sacrificed 24 h after the administration of each hepatotoxin. Data are
expressed as meansF S.E.M. (n= 6) and analyzed by one-way analysis of
variance. Normal control: 145.2F 5.96 and sodium tungstate: 148.8F 6.05.
In each case, the hepatotoxin alone treated group was compared with the
group supplemented with sodium tungstate followed by necrogenic dose of
the respective hepatotoxin. The levels of statistical significance were
**P < 0.01 and *P< 0.05.
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followed by various hepatotoxins
The content of hepatic malondialdehyde, an accepted
indicator of oxidative stress, increased significantly after the
administration of either of the hepatotoxins. However, as
evident from Fig. 4, this increase was much more significant
in CCl4, TAA, or CHCl3 alone treated groups when com-
pared with the groups treated with BB or AAP. Excess
generation of ROS in livers from CCl4-, TAA-, or CHCl3-
treated rats may be attributed to the increased activity of XO
(Fig. 6), which generates ROS while catalyzing its reaction.
Pretreatment with tungstate followed by treatment with
hepatotoxins could alleviate the CCl4-, TAA-, or CHCl3-
induced rise in lipid peroxidation.
3.3. Reduced glutathione in rats treated with tungstate
followed by the induction of necrosis
Fig. 5 depicts the status of hepatic reduced glutathione in
CCl4-, TAA-, or CHCl3-treated rats. An enhanced oxidative
stress due to free radical reactions is expected to consume
the pool of this endogenous tripeptide, thereby depleting its
level in the tissue. A decrease in the hepatic GSH concen-
tration seems to be the result of an effort by the tissue to
counteract the effect of ROS, which is suggested to generate
in excess due to the increased xanthine oxidase activity after
CCl4, TAA, or CHCl3 exposure. Pretreatment with tungstate
appears to replenish the depleted GSH levels in these groupsFig. 5. Reduced glutathione content in liver tissue of rats pretreated with
sodium tungstate followed by induction of necrosis in different groups of
rats given different hepatotoxins. Dose and the treatment protocol have
been described in the text. Rats were sacrificed 24 h after the administration
of each hepatotoxin. Data are expressed as meansF S.E.M. (n= 6) and
analyzed by one-way analysis of variance. Normal control: 320.2F 9.05
and sodium tungstate: 315.2F 6.07. In each case, the hepatotoxin alone
treated group was compared with the group supplemented with sodium
tungstate followed by necrogenic dose of the respective hepatotoxin. The
levels of statistical significance were **P < 0.01 and §P< 0.1.
Fig. 6. Effect of sodium tungstate pretreatment on XO activity in necrotic
tissue. Necrosis was induced by different hepatotoxins given to various
groups as per the dose and treatment protocol described in the text. Rats were
sacrificed 24 h after the administration of each hepatotoxin. Data are
expressed as meansF S.E.M. (n= 6) and analyzed by one-way analysis of
variance. Normal control: 292.5F 7.98 and sodium tungstate: 279.8F 7.63.
In each case, the hepatotoxin alone treated group was compared with the
group supplemented with sodium tungstate followed by necrogenic dose of
the respective hepatotoxin. The levels of statistical significance were
**P < 0.01 and *P< 0.05.
Table 1
Effect of XO inhibitor and ROS scavenger on biochemical markers of








NC 33.5F 4.40 142.2F 6.25 151.5F 6.43
AP 30.8F 3.12 137.0F 5.58 146.0F 6.67
DMSO 32.8F 3.23 138.6F 6.23 143.8F 5.93
CCl4 246.0F 7.91 225.5F 8.09 571.4F 12.03
AP+CCl4 174.4F 6.34** 190.1F 7.11* 520.7F 7.41**
DMSO+CCl4 197.1F 6.87** 203.0F 8.68
§ 510.0F 8.60**
TAA 111.5F 5.55 193.3F 7.32 220.8F 8.63
AP+TAA 52.0F 5.48** 144.6F 6.34** 158.1F 6.05**
DMSO+TAA 74.0F 4.50** 170.1F 7.22§ 190.0F 7.63*
CHCl3 101.2F 5.80 198.0F 7.24 474.0F 10.53
AP+CHCl3 87.0F 4.43
§ 172.8F 7.80* 438.3F 8.17*
DMSO+CHCl3 80.0F 5.14* 184.6F 6.60 451.6F 9.44
FHF 2711.7F 65.87 4288.5F 67.73 515.2F 11.27
AP+ FHF 1283.3F 41.31** 2662.2F 45.69** 343.0F 9.22**
DMSO+FHF 1655.5F 55.24** 2902.0F 49.97** 413.3F 9.73**
Serum transaminases and lipid peroxidation were determined 24 h after the
administration of each hepatotoxin. Data are expressed as meanF S.E.M.
(n= 6) and analyzed by one-way analysis of variance. In each case, the
hepatotoxin alone treated group was compared with the group supple-
mented with sodium tungstate followed by respective hepatotoxin. The
levels of statistical significance were **P< 0.01, *P < 0.05 and §P < 0.1.
AP: allopurinol; DMSO: dimethyl sulfoxide; CCl4: carbon tetrachloride;
TAA: thioacetamide; CHCl3: carbon tetrachloride; sALT: serum alanine
aminotransferase; sAST: serum aspartate aminotransferase; LPO: lipid
peroxidation, FHF: fulminant hepatic failure; NC: normal control.
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thereby sparing GSH. Even in rats with FHF, where GSH
depletion was more severe (74.6F 5.11 vs. 317.0F 6.93),
tungstate treatment could cause a significant increase in
GSH (Table 3).
The rats treated with BB, or AAP showed a much more
depletion in GSH level, when the results were compared to
the groups receiving CCl4, TAA, or CHCl3 (Fig. 5). GSH
content, which was 320.2F 9.05 in normal control rats,
decreased to 64.2F 5.10 and 89.0F 6.07, respectively, in
BB- and AAP-treated groups. Pretreatment with tungstate
prior to BB or AAP treatment had no effect on GSH level,
suggesting that the severe depletion in GSH level may not be
the result of enhanced radical reactions as was observed in
CCl4-, TAA-, or CHCl3-induced liver necrosis. Conjugation
of BB-, or AAP-intermediates with GSH may explain this
depletion.
3.4. Tungstate and hepatic xanthine oxidase activity
Treatment with CCl4, TAA, or CHCl3 resulted in a
significant induction in XO activity, confirming the involve-
ment of XO-derived ROS in the pathogenesis of liver
necrosis and FHF produced by these hepatotoxins (Fig. 6,
Table 3). Pretreatment with tungstate prior to the induction
of liver necrosis by CCl4, TAA, or CHCl3 could inhibit the
hepatotoxin-mediated rise in XO activity. Further, decreased
XO activity is clearly seen to be associated with a reductionin lipid peroxidation in both necrotic (Fig. 4) and FHF rats
(Table 3), suggesting that tungstate treatment could alleviate
the lesions inflicted by ROS only. Contrary to this, no
induction in the XO activity was observed in BB- or
AAP-induced liver injury, and thus tungstate pretreatment
failed to prevent or inhibit the liver injury associated with
these hepatotoxins.
3.5. Effect of allopurinol or DMSO on ROS-mediated
hepatic injury
Allopurinol and DMSO were used to reinforce the role of
XO and of ROS in the process. Serum ALT/AST and lipid
peroxidation were measured to validate the hypothesis,
suggesting the mechanism of protection of liver injury by
tungsten. Tungstate was hypothesized to protect tissue
injury by mitigating ROS. Protection of hepatic injury either
by AP or by DMSO confirms the hypothesis. As shown in
Table 1, induction of liver necrosis/FHF in various group of
rats resulted in a marked increase in biochemical markers of
hepatic dysfunction (sALT, sAST) and oxidative stress
(LPO). Treatment of animals with XO inhibitor or ROS
scavenger could significantly bring down the levels of these
parameters. The effect was seen in rats treated with CCl4,
TAA, or CHCl3, where injury is mediated by ROS. Even in
FHF, treatment with AP or DMSO could cause a significant
decrease in these biochemical parameters (Table 1). Inhibi-
tion of liver injury by ROS scavenger provides an evidence
Fig. 7. Survival rate in rats pretreated with sodium tungstate (50 mg/kg
b.wt., orally for 7 weeks) followed by lethal dose (LD90) of each of the
hepatotoxin to various groups. Dose and the treatment protocol have been
described in Materials and methods. Nine out of ten rats died in groups
receiving LD90. Tungstate pretreatment caused 50%, 60%, or 20% increase
in survival when compared to rats receiving lethal doses of CCl4, TAA, or
CHCl3, respectively. The group of rats receiving sodium tungstate alone
showed 100% survival.
Table 3












NC 290.0F 6.83 153.5F 6.20 317.0F 6.93
ST 285.6F 4.98 151.0F 6.00 314.1F 6.72
FHF 1125.0F 28.45 512.3F 9.85 74.6F 5.11
ST+ FHF 580.4F 15.53** 371.5F 8.79** 113.1F 4.24**
Biochemical estimations were performed on the tissue samples obtained from
rats with FHF. Animals were sacrificed 4 h after inducing FHF by TAA, as
has been described in the text. Values are meansF S.E.M. of six rats. TAA
alone treated group was compared with the group supplemented with sodium
tungstate followed by TAA. The level of statistical significance was
**P< 0.01. NC: normal control; ST: sodium tungstate: TAA: thioacetamide.
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injury/lipid peroxidation by XO inhibitor suggests that XO-
catalyzed reaction is an important source of free radicals. As
shown earlier (Fig. 6 and Table 3), XO is increased in liver
injuries produced by CCl4, CHCl3, or TAA as well as in
FHF. No increase in XO activity was seen in BB- or AAP-
induced liver injury, where glutathione conjugation with
BB- or AAP-intermediates is considered to be the cause of
severe GSH depletion/oxidative injury.
3.6. Survival studies
The lethal dose selected to study survival rate in rats
treatedwith tungstate was the respective LD90 dose of various
hepatotoxins used. It killed 9 out of 10 rats, as observed in twoTable 2







NC 34.0F 5.04 133.4F 6.08 7.10F 0.16
ST 31.8F 4.77 131.0F 8.09 6.82F 0.25
FHF 2720.3F 70.20 4300.6F 50.28 23.82F 2.38
ST+ FHF 1440.2F 60.38** 2400.0F 60.48** 14.28F 2.37*
Enzyme activity was determined 4 h after inducing FHF by intraperitoneal
injection of TAA as per the dose and treatment protocol described in the
text. Values are meansF S.E.M. of six rats. TAA alone treated group was
compared with the group supplemented with sodium tungstate followed by
intraperitoneal injections of TAA. The levels of statistical significance were
**P < 0.01 and *P < 0.05. sALT: serum aminotransferase; sAST: serum
aspartate aminotransferase; sALP: serum alkaline phosphatase; NC: normal
control; ST: sodium tungstate: TAA: thioacetamide.different sets of experiments. Pretreatment with tungstate for
7 weeks prior to the administration of lethal doses resulted in
an appreciable decrease in the mortality induced by the CCl4,
TAA, or CHCl3. Tungstate pretreated groups exhibited a
decrease in mortality up to, respectively, 50%, 60%, or
20% in comparison to rats receiving LD90 of CCl4, TAA, or
CHCl3. No decrease in mortality was observed in groups
treated with BB or AAP followed by tungsten. Tungstate
alone treated group, which served as a control group, showed
no signs of mortality (Fig. 7).
3.7. Effect of tungstate on TAA-induced FHF
Induction of FHF by TAA resulted in a drastic elevation in
the levels of serum aminotransferases and alkaline phospha-
tase (Table 2), as also reported by others. We observed a
significant increase in hepatic lipid peroxidation and GSH
depletion in FHF rats (Table 3). An increase in the level of
malondialdehyde (512.3F 9.38) was observed when FHF
animals were compared to normal controls (153.5F 6.20).
As expected, an inverse correlation of malondialdehyde
levels with GSH was observed. Pretreatment with tungstate
could significantly lower the TAA-induced rise in serumTable 4
Liver weight/body weight ratio and hepatic protein content in control and
treated groups of rats
Liver/body weight 103 Total protein in mg/gram of liver
NC 23.0F 0.84 132.8F 4.50
ST 23.5F 0.77 135.0F 4.70
CCl4 23.1F 0.86 125.7F 3.92
ST+CCl4 23.4F 1.13 129.0F 5.00
TAA 22.8F 1.05 124.0F 4.41
ST+TAA 23.3F 0.82 128.1F 4.84
CHCl3 23.0F 0.91 128.0F 4.43
ST+CHCl3 23.2F 0.90 130.5F 4.91
Values are meansF S.E.M. of six rats. No significant difference was
observed in either liver/body weight ratio or total protein content when
individual experimental groups were compared with the normal control.
NC: normal control; ST: sodium tungstate; CCl4: carbon tetrachloride;
TAA: thioacetamide; CHCl3: carbon tetrachloride.
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of significance, when compared to the TAA alone treated
group of rats, was < 0.01. Also the levels of lipid peroxida-
tion and reduced glutathione were alleviated after tungstate
pretreatment (P < 0.01).
3.8. Effect of tungstate on liver weight/body weight ratio,
and hepatic protein content in rats with liver necrosis
To ascertain whether the changes reported by tung-
state were not due to change in liver size, liver weight/
body weight ratio and hepatic protein content wereFig. 8. Effect of sodium tungstate (ST) on liver architecture in rats treated with var
(b), CCl4-treated (c) TAA-treated (e), and CHCl3-treated (g) rats. Slides d, f, and
followed by CCl4, TAA, or CHCl3.determined. As shown in Table 4, treatment with either
hepatotoxins or with sodium tungstate followed by
different hepatotoxins did not caused any significant
change in the liver weight/body weight ratio or hepatic
protein content.
3.9. Effect of tungstate on liver histology of control and
treated rats
Histological studies on rats treated with various hepato-
toxins were performed to ascertain the cause of hepatic cell
death, and to provide further evidence to support theious liver toxins. Photograph shows the sections from normal (a), ST-treated
h, respectively, depict the sections of livers obtained from rats given ST
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8 (c, e, g), hepatic cell death induced by the specified doses
of CCl4, TAA, or CHCl3 is observed to be restricted to
necrosis. No appearance of apoptotic bodies was seen in any
of the slides.
In CCl4-treated rats, section shows necrosis of hepato-
cytes with collapse of hepatic architecture and hemorrhage.
Sodium tungstate given before CCl4 administration could
afford protection as evident by the necrotic parts with areas
of normal liver architecture. The liver section of CHCl3-
treated rats also shows necrosis of hepatocytes with liver
architecture destruction, hemorrhage, and inflammatory
infiltrate in the portal tracts. Changes improved in tung-
state-treated rats, which exhibited areas of normal hepato-
cytes and patches of necrotic hepatocytes. Severe
hepatocytic necrosis and hemorrhages with distortion of
hepatic architecture are the prominent features seen after
TAA administration. These changes were almost absent
(except for a few necrotic areas) in sections of liver
obtained from rats receiving tungstate followed by TAA
(Fig. 8). Rats treated with tungstate alone showed no sign
of damage (Fig. 8b) when compared to the normal control
(Fig. 8a).4. Discussion
Hepatic lesions produced as a result of oxidative stress
are of wide occurrences in both clinical and experimental
animal studies. A large number of chemicals inflict liver
damage like necrosis or FHF by producing oxidative stress
in different animal species [3–7]. Often the injury is
mediated by free radicals or by the depletion of endogenous
pool of antioxidants such as GSH [8,9]. The compounds
used in this study to induce liver damage may be put in
either one of the two categories. CCl4, TAA, and CHCl3 are
the classic models where the free radicals directly produce
liver injury. They mediate their toxicity via the formation of
free radicals especially the ROS, which interact with the
membrane unsaturated lipids, consequently promoting lipid
peroxidation [31,33,34]. BB and AAP, on the contrary, are
metabolized into electrophilic products, which readily con-
jugate with GSH, resulting in an extensive GSH depletion,
thereby altering the reduced status of the tissue, and causing
tissue injury. Liver injury produced by these aromatic
hydrocarbon derivatives is caused by the covalent binding
of their respective reactive metabolites to the cellular macro-
molecules [35,36].
The necrotic doses of the abovementioned compounds
given to rats significantly elevated the transaminases and
ALP activity levels (Figs. 1–3). The results were consistent
with the literature [31,32]. Animals were sacrificed 24 h after
the hepatotoxin administration. Tissue injury at this time
point has earlier been investigated by others [5,37,38].
Tungsten could effectively alleviate the liver injury caused
by CCl4, TAA, or CHCl3 as indicated by the decrease in theactivity levels of sALT (Fig. 1), sAST (Fig. 2) and sALP
(Fig. 3). The changes reported here by tungstate were not
due to change in liver size, as neither of these toxins affected
total protein or liver weight/body weight ratio (Table 4).
Tungsten, however, failed to attenuate the damage when
given prior to BB or AAP, indicating that the oxyanionic
form of tungsten was effective in inhibiting the progression
of free radical-induced liver injury only, as seen in the case
of CCl4, TAA, or CHCl3.
FHF is another serious complication of the liver. Tung-
sten in the form of sodium tungstate could prevent TAA-
induced FHF in Wistar rats (Tables 2 and 3). This model has
previously been characterized by clinical, biochemical and
histopathological methods and proved to be a reliable and
satisfactory model of FHF and hepatic encephalopathy
[39,40]. Significant decrease in the activity of sALT, sAST
and sALP was observed in rats receiving tungstate treatment
followed by TAA (Table 2). Animals were sacrificed 4
h after inducing FHF.
Tungstate as an oxyanion may catalyze sulfuryl transfer
reactions and can mimic insulin uptake in vitro [15].
Tungstate therapy is already known and utilized as a
nontraditional folk medicine in Japan. It has been about
20 years since Kase proposed therapeutic effects of tung-
state [41]. The accumulated experience with tungsten gives
us insight into the nature of the metal in conjunction with
the molecular mechanisms of its oxyanionic form on insulin
receptors. Present investigation reports the protective role of
tungstate in injuries produced by various liver toxins.
Tungstate is hypothesized to protect injury by causing
inhibition of some of the critical reaction(s), which generate
free radicals. Alternately, it may check the progression of
liver injury induced by radical generating compounds such
as TAA, or CCl4. In this perspective, the activity level of rat
liver xanthine oxidase was determined. Xanthine oxidase is
an endogenous source of ROS that can produce oxidative
stress, which inflicts tissue injury. The data generated in this
study reveal that XO activity is increased in CCl4-, TAA-, or
CHCl3-induced necrosis and FHF, indicating its role in liver
injury by these chemicals.
Oxidative damage is the result of oxidative stress pro-
duced in the tissue either due to increased production of free
radicals or due to depleted levels of antioxidant defense
molecules such as glutathione. Oxidative stress affects many
cellular functions by various mechanisms such as the
alteration in gene expression through activation of transcrip-
tion factor NF-nB or induction of permeability transition
(PT) in mitochondria with lethal consequences [42]. Hepatic
injury induced by various chemicals in this study is attrib-
uted to oxidative stress.
As shown in Table 1, like tungstate, treatment of rats
with XO inhibitor allopurinol, or ROS scavenger DMSO,
could alleviate liver injury. This experiment reinforces the
role of XO, and ROS in the process and helps validate the
hypothesis that tungstate probably acts by mitigating ROS
generated during XO-catalyzed reaction. Attenuation of
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stress in liver injury. XO-derived ROS does also contribute
to the TAA-induced FHF, as a significant increase in XO
activity has been observed in FHF rats (Table 3).
Normal fluxes of pro-oxidants serve useful functions at
the cellular and whole organism level. The continual for-
mation of ROS is a physiological necessity and an unavoid-
able consequence of oxygen metabolism. However, when
generated in excess, they can be toxic. Structural and
functional alterations associated with the exposure of the
tissue to a wide variety of factors including many chemicals
are understood to be mediated by ROS, which are generated
at both intercellular and intracellular level [43]. At the
intercellular level, activated phagocytic cells (like Kupffer
cells, macrophages, and neutrophils) release ROS. At the
intracellular level, all cells have the capacity to generate
ROS. In hepatocytes, for example, 2–5% of the total O2
consumed by mitochondria is converted to ROS [44].
Oxidases such as enzyme xanthine oxidase have been
postulated as important cellular sources of ROS. Their
possible involvement in the manifestation of toxicities of
potential toxins has been suggested [45]. XO activity is
reported to increase in several disorders including brain
tumors [46]. Hepatotoxicity after certain viral infections has
also been suggested to be due to the induction of XO and
concomitant oxygen radical production [47]. XO catalyzes
the oxidation of hypoxanthine to xanthine and of the latter
to uric acid. The enzyme exists in two forms, a dehydroge-
nase and an oxidase form. Both forms generate ROS, but
under physiological conditions, xanthine oxidase exists
predominantly in dehydrogenase form [48], which is
inhibited by NAD+. Since the cells normally contain large
amounts of NAD+, dehydrogenase form has no physiolog-
ical significance. The conversion of the dehydrogenase form
to oxidase can occur by proteolysis [48] or by reversible
oxidation of sulfhydryl groups [49]. While oxidizing its
substrate, XO uses oxygen as an electron acceptor and
generates superoxide anion radical and hydrogen peroxide
as by-product [50]. In this report, XO is shown to increase
in liver lesions produced by CCl4, TAA, or CHCl3 (Fig. 6).
Prophylactic treatment of rats with tungstate restores the
normal levels of various biochemical parameters altered in
response to these chemicals (Figs. 1–4). Significant nor-
malization by tungstate in various biochemical parameters
associated with liver injury and oxidative stress and a
decrease in XO activity level were also observed in FHF
rats (Tables 2 and 3). Production of ROS in necrosis and
FHF was proved by measuring malondialdehyde content
and reduced glutathione as indicators of ROS generation
(Figs. 4 and 5, and Table 3).
ROS, as discussed previously, cause the peroxidation of
membrane lipids, thereby resulting in the release of cyto-
solic enzymes into the plasma. XO is a molybdenum-
containing enzyme [51]. The chronic feeding of rats with
tungstate for 7 weeks in this study was sufficient to replace
molybdenum from the enzyme as tungsten shares manychemical and physical properties with molybdenum and
serves as a biological antagonist of molybdenum uptake
and utilization [51,52]. The oxyanionic form had the ad-
vantage of easy uptake by the tissue.
Suppression of XO activity by tungstate resulted in the
reduced generation of ROS, which generally attacks on
almost all types of biomolecules in vicinity such as mem-
brane lipids. In the present study, we observe that in
tungsten-treated group, the hepatic lesions produced by
the free radical generating compounds were markedly
alleviated. The levels of TBARS were also brought down
close to normal values. An increase in hepatic malondialde-
hyde content of the tissue, which may be considered as a
marker of the oxidative tissue damage, provides evidence
supporting the role of XO-derived ROS in CCl4-, TAA-, or
CHCl3-induced necrosis, and in TAA-induced FHF. How-
ever, changes in the MDA content prove, in part, that the
anti-hepatotoxic effects of the pretreatment with tungstate
were due to the inhibition of free radical formation. The
effect of tungstate was so marked that it could cause a
noticeable decrease in the mortality in rats receiving lethal
doses of CCl4, TAA, or CHCl3 (Fig. 7).
A growing body of evidence indicates that reduced
glutathione (GSH) plays a vital role in cellular function. It
detoxifies toxic metabolites of drugs, regulates gene expres-
sion, apoptosis, and transmembrane transport of organic
solutes [12]. GSH, which constitutes one of the physiolog-
ically important mechanisms to curtail progression of tissue
damage, is generally affected under conditions of oxidative
stress [53]. Depletion of GSH in the liver after the admin-
istration of CCl4, TAA, or CHCl3 makes tissue susceptible
to damage, indicating the occurrence of radical reactions in
necrosis and FHF. Tungstate could replenish hepatic GSH
level (Fig. 5, and Table 3) in rats with necrosis/FHF.
GSH is a unique cellular tripeptide capable of acting as a
nucleophilic scavenger and a cofactor in GSH peroxidase-
mediated destruction of peroxides and hydroperoxides. It is
essential to maintain the reduced status of the cell/tissue,
and its severe depletion is reported to lead to oxidative
tissue injury. Liver injury produced by CCl4, TAA, or
CHCl3 involves the formation of ROS, which is mitigated
by GSH resulting in its excess demand. GSH, besides its de
novo synthesis, is recycled from oxidized glutathione
(GSSG) at the expense of NADPH. Its reduced form, after
combating the effects of peroxides/hydroperoxides, is con-
verted to the oxidized form. More amount of GSH will be
synthesized and utilized in response to tissue insult by ROS.
An inhibition of excessive ROS generation following tissue
injury is expected to result in a large unused pool of GSH,
which would be the resultant of its de novo synthesis and
recycling. A high level of lipid peroxidation in necrosis/FHF
(Fig. 4, Table 3) is observed following CCl4, TAA, or
CHCl3 treatment, which leads to GSH depletion. Tungsten
treatment (Fig. 5, Table 3) could increase the pool of unused
GSH, indicating that tungsten checks the generation of
ROS, thereby sparing GSH. Once excessive ROS produc-
Table 5
Summary of the results depicting the effects of tungsten on different types
of hepatic lesions
Animal model Type of injury Effect
Carbon tetrachloride Necrosis Protective
Chloroform Necrosis Protective
Thioacetamide Necrosis Protective
Acetaminophen Necrosis No effect
Bromobenzene Necrosis No effect
Thioacetamide FHF Protective
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accumulating in the cell/tissue, and a high level of GSH is
detected. In BB- or AAP-treated groups, tungsten treatment
could not restore the depleted GSH levels. Studies have
revealed that biochemical activation of BB or AAP causes
GSH depletion due to GSH adduct formation [11,12], and
not because of the generation of ROS. On the contrary, free
radical generating compounds (CCl4, TAA, or CHCl3) being
investigated in this study are suggested to act by inducing
XO activity (Fig. 6), which produces oxidative stress by
generating ROS as by-product. Tungsten, as shown in Fig.
6, inhibits XO activity, and results in a decreased production
of ROS, which caused tissue damage. However, in BB or
AAP groups, GSH could not be recycled as it was meta-
bolically used up in the formation of adducts with BB-, or
AAP-metabolites. This probably explains the severe GSH
depletion observed in these groups. Since no ROS produc-
tion is associated with BB-, or AAP-induced liver injury,
tungsten, which is hypothesized to mitigate ROS, had no
effect of GSH contents in these two groups.
Binding of electrophilic intermediates, 3,4-bromoben-
zene epoxide and N-acetyl-p-benzoquinone imine, of BB
and AAP, respectively, with GSH yield glutathionyl conju-
gate resulting in GSH depletion [11,12]. This depletion
makes liver cells more susceptible to ROS-mediated injuries
(Figs. 4 and 5). As reported earlier, binding of the reactive
metabolites of BB or AAP to liver proteins cause tissue
damage. At higher doses of these compounds, a significant
increase in the mortality is observed. However, unlike the
free radical generating compounds, tungsten could not cause
a reduction in mortality in these groups (Fig. 7), indicating
that it is not merely the oxidative stress, but the ROS-
mediated oxidative stress that is inhibited by tungsten.
Further, tungsten may inhibit the progression of liver injury
by other mechanisms such as by modulation of signal
transduction pathway. Tungstate at low doses of 0.1–1
mM stimulates adenylate cyclase in a rapid and reversible
manner [54]. The stimulation of adenylate cyclase by
tungstate can act as a contributory factor in free radical
mediated necrosis or FHF. However, this hypothesis lacks
evidence and needs validation.
Conversion of the dehydrogenase form of the enzyme
to the oxidase form can be induced by many compounds
[55], and might be a consequence of the oxidant moieties
generated as a result of primary or secondary oxidative
reactions initiated by CCl4, TAA, or CHCl3 within the cell.
However, the mechanism by which XO is induced in
CCl4-, TAA- or CHCl3-treated group of rats is not clear.
A possible explanation to this may be the oxidation of
xanthine dehydrogenase by the reactive oxygen moieties
produced by CCl4, TAA or CHCl3. Xanthine dehydroge-
nase has been reported to undergo reversible oxidation at
its sulfhydryl group to form XO [48]. Since ROS are not
produced by BB or AAP, conversion of dehydrogenase
form to the oxidase form does not occur in these animal
models.In summary, studies reported in this paper suggest that
ROS-generating enzyme xanthine oxidase is induced in rats
treated with free radical generating compounds, but not with
the compounds producing oxidative stress by causing GSH
depletion directly (Table 5). The oxyanionic form of tung-
sten can effectively inhibit xanthine oxidase, thereby pre-
venting the generation of free radicals, which cause injury to
the tissue.Acknowledgements
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